Ultrasound-responsive thrombus treatment with zinc-stabilized gelatin nano-complexes of tissue-type plasminogen activator. by Uesugi, Yoshiko et al.
Title Ultrasound-responsive thrombus treatment with zinc-stabilizedgelatin nano-complexes of tissue-type plasminogen activator.
Author(s)Uesugi, Yoshiko; Kawata, Hiroyuki; Saito, Yoshihiko; Tabata,Yasuhiko
CitationJ urnal of drug targeting (2012), 20(3): 224-234
Issue Date2012-04
URL http://hdl.handle.net/2433/174341





Ultrasound-responsive thrombus treatment with zinc-stabilized 












Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical 
Sciences, Kyoto University, 53 Kawara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan 
b 
First Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, 
Nara 634-8522, Japan 
 

Corresponding author: Yasuhiko Tabata 
Department of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical 
Sciences, Kyoto University, 53 Kawara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan 
Tel.: +81 75 751 4121; Fax: +81 75 751 4646; E-mail: yasuhiko@frontier.kyoto-u.ac.jp 
 
Short title: Ultrasound-responsive t-PA nano complexes 
 






ABSTRACT    
This study is undertaken to design zinc-stabilized gelatin nano-complexes of tissue-type 
plasminogen activator (t-PA) for thrombolytic therapy where the t-PA activity can be recovered 
in the blood circulation upon ultrasound irradiation. Various molecular weights of gelatin were 
complexed with t-PA by their simply mixing in aqueous solution. Then, zinc acetate, calcium 
acetate or magnesium acetate was added to form nano-sized gelatint-PA complexes. The 
complexes had the apparent molecular size of about 100 nm. When zinc ions were added to the 
gelatint-PA complexes, the t-PA activity was suppressed most strongly to 57% of the original, 
free t-PA activity. Upon ultrasound exposure in vitro, the t-PA activity was fully recovered. A 
cell culture experiment with L929 fibroblasts demonstrated no cytotoxicity of complexes at the 
concentration used for the in vivo experiment. The half-life of t-PA in the blood circulation 
prolonged by the complexation with gelatin and zinc ions. The zinc-stabilized t-PAgelatin 
complex is a promising t-PA delivery system which can manipulate the thrombolytic activity 




In acute myocardial infarction, treatment strategies aimed at rapidly restoring complete and 2 
persistent coronary flow, and the recanalisation of infarct artery is the target of both 3 
pharmacological and mechanical reperfusion techniques. Tissue-type plasminogen activator 4 
(t-PA) is widely used as a thrombolytic drug because of its high fibrin specificity (Armstrong  5 
Collen, 2001) and efficacy if administered early. However, t-PA has some adverse effects to be 6 
clinically resolved, including the risk of allergic reactions, bleeding complications, and short 7 
half-life (Blann et al., 2002; Bode et al., 1996; Turpie et al., 2002), which often limits the 8 
therapeutic applications. In fact, among patients treated with plasminogen activators, 9 
approximately 20% showed the adverse effect of bleeding (Chung et al., 2008). Therefore, the 10 
targeted delivery of thrombolytic drugs only to the necessary site is an attractive strategy to 11 
avoid such side effects. Drug delivery system (DDS) is a technology or methodology to 12 
efficiently delivery drugs to the site of action by making use of carrier materials. For the 13 
thrombolytic applications, several investigations on the delivery of t-PA have been reported 14 
(Chung et al., 2008; Tiukinhoy-Laing et al., 2007; Shaw et al., 2009; Heeremans et al., 1995; 15 
Smith et al., 2010; Molina et al., 2006; Collis et al., 2010).  16 
Recently, an increasing interest has been expressed in intelligent DDS that has the capacity 17 
for triggered release by external factors, such as ultrasound, temperature, pH, or 18 
electromagnetic fields (Tiukinhoy-Laing et al., 2007;  Rapoport et al., 2002; Marin et al., 2001; 19 
Daocheng and Mingxi, 2008; Frinking et al., 1998; Huang and MacDonald, 2004). Among 20 
these factors, ultrasound is one of the attractive methodologies to control drug release, as it is 21 
non-invasive and can deeply penetrate into the interior of body. Several systems of 22 
ultrasound-triggered drug release, specifically the poly (DL lactide-co-glycolide) system
 
23 
(Frinking et al., 1998) and acoustically active liposomes (Huang and MacDonald, 2004),
 
have 24 
been reported. However, all of the ultrasound triggered release systems cannot be used 25 
 3 
 
clinically because of their low sensitivity in response to ultrasound stimulation and the poor 1 
drug loading. 2 
To date, we have explored various DDS carriers of gelatin. Gelatin has been extensively 3 
used for industrial, pharmaceutical, and medical applications, and the bio-safety has been 4 
proved through the long clinical usages as surgical biomaterials and drug ingredients (Veis, 5 
1965). Biodegradable hydrogels of gelatin and the derivatives have been designed for the 6 
controlled release of various drugs, such as basic fibroblast factor (bFGF) (Ikada and Tabata, 7 
1998), bone morphogenetic protein-2 (BMP-2) (Yamamoto et al., 1998), transforming growth 8 
factor beta 1 (TGF-1) (Yamamoto et al., 2000), hepatocyte growth factor (HGF) (Ozeki et al., 9 
2001), NK4 plasmid DNA (Kushibiki et al., 2004a), matrix metalloproteinase-1 (MMP-1) 10 
plasmid DNA (Aoyama et al., 2003; Lin et al., 2009), small interfering RNA (Nakamura et al., 11 
2008), simvastatin (Tanigo et al., 2010), and cisplatin (Konishi et al., 2003). In addition, gelatin 12 
and the water-soluble chemical derivatives have been used to improve the in vivo stabilization 13 
and targeting of drugs (Kushibiki and Tabata, 2005) as well as form polymer micelles for drug 14 









ions, have been used as the cross-linker for nanoparticles preparation (Jay and Saltzman, 2009; 16 
Jay et al., 2008; Mørch et al., 2006). In addition, about 2 g of zinc ions are known to be present 17 
in the adult human body and the ions play an important role in the activity of many metal and 18 
metal-activated enzymes (Krebs, 2000).
 
19 
In this study, a novel delivery system for t-PA where the activity is locally switched on by 20 
ultrasound was designed, and the thrombolytic effects were evaluated. As the t-PA carrier, the 21 
gelatin and metal ions were used. The complexes of t-PA with the gelatin and metal ions were 22 
characterized in terms of the physicochemical properties and the thrombolytic activity. The 23 
t-PA activity of complexes was examined before and after ultrasound exposure to assess the 24 
potential of ultrasound-induced activity recovery. We examine the retention in the blood 25 
 4 
 
circulation and tissue distribution of t-PA complexes administered intravenously.  1 
 2 
MATERIALS AND METHODS 3 
Materials 4 
Gelatin samples with an isoelectric point (IEP) of 9.0 (weight-averaged molecular weight 5 
(MW) = 2,000, 3,000, 5,000, 20,000, 50,000, and 100,000) prepared by an acid process of pig 6 
skin type I collagen, were kindly supplied from Nitta Gelatin Inc., Osaka, Japan. Zinc acetate 7 
(Zn(CH3COO)2) solution, magnesium acetate (Mg(CH3COO)2∙4H2O), and calcium acetate 8 
(Ca(CH3COO)2∙H2O) were purchased from Nacalai Tesque Inc., Kyoto, Japan. t-PA (Cleactor
®
 9 
administration 1,600,000) was purchased from Eisai Co., Ltd., Tokyo, Japan. Chromozym t-PA 10 
was purchased from Roche Diagnostics, Germany. Plasmin, plasminogen, and thrombin 11 
isolated from the human plasma were obtained from EMD Biosciences Inc., CA. 12 
Plasminogen-free fibrinogen from the human plasma was purchased from Sigma-Aldrich 13 
Corp., MO. Other chemicals of the purest quality were obtained. 14 
 15 
t-PA assay with a peptidic substrate 16 
The hydrolytic activity of t-PA was determined by the conventional assay with a synthetic 17 
substrate (Chromozym t-PA, Roche Diagnostics, Germany). Briefly, 20 l of t-PA solution and 18 
20 l of different concentrations of zinc acetate were mixed and incubated at 37°C for 30 min. 19 
Then, 15 l of the mixture was added to 150 l of Chromozym t-PA solution containing 90 mM 20 
Tris buffer (pH 8.5) and 0.14 wt% Tween 80. After incubation at 37°C for 30 min, the reaction 21 
was stopped by addition of 75 l of 10 vol% citric acid. The absorbance at 405 nm of the 22 
reaction mixture (200 l) was measured on a microplate reader (VERSAmax, Molecular 23 




Preparation of t-PA complexes with gelatin and metal ions  1 
To prepare the complexes of t-PA and gelatin, 10 mg of gelatin with different molecular 2 
weights  in 10 mM phosphate-buffered solution (PBS, pH 7.4) (0.25 ml) was mixed with 0.5 ml 3 
of PBS containing 0.5 mg of t-PA. After agitation at 37°C for 30 min, different concentrations 4 
of zinc acetate, magnesium acetate, or calcium acetate (0.25 ml) were added to the mixture, 5 
followed by agitation at 37°C for 30 min to prepare the complex of t-PA with gelatin and metal 6 
ions.  7 
 8 
Measurement of apparent molecular size of t-PA complexes with gelatin and zinc ions 9 
      The apparent molecular size of t-PA complexes with gelatin and zinc ions was measured by 10 
dynamic light scattering (DLS) apparatus (DLS-7000, Otsuka Electronic, Osaka, Japan) 11 
equipped with an Ar
+
 laser at a detection angle of 90° at 37°C. The autocorrelation function of 12 
samples was analyzed based on the histogram method and Rs value was calculated 13 
automatically by the equipped computer software. The experiments were done 3 times 14 
independently for each sample. 15 
 16 
Assay of t-PA activity by fibrin plate method 17 
To determine the in vitro thrombolytic activity of t-PA, a fibrin clot lysis assay was 18 
performed according to the conventional plasminogen-rich fibrin plate method (Astrup and 19 
Müllertz, 1952). Briefly, 0.4 wt% human fibrinogen solution (10 ml) in 0.17 M borate buffer 20 
(pH 7.8) was poured into a 10-cm petri dish (Flat). Plasminogen (0.2 ml, 50 U/ml) was added to 21 
the fibrinogen solution. Clotting was induced by adding 0.2 ml of human thrombin (100 U/ml), 22 
followed by leaving for 30 min at room temperature to allow the clot formation. Then, 2 l of 23 
PBS solution containing t-PA or t-PA complexes with gelatin and metal ions was carefully 24 
placed onto the plate. After incubation at 37°C for 1 hr, the diameter of clear zones was 25 
 6 
 
measured while the standard curve between the diameter and the activity was prepared using 1 
human plasmin at determined concentrations. The percent activity was calculated as the 2 
percentage of sample activity to that of free t-PA. The experiment was done at least 3 times 3 
independently for each sample. 4 
To evaluate the t-PA activity in bovine serum albumin (BSA) solution, the similar assay 5 
procedure was performed except that various solutions of t-PA complex were incubated with 6 
42 mg/ml of BSA for 90 min at 37°C before the t-PA activity assay. 7 
To evaluate the t-PA activity before and after ultrasound irradiation in vitro, various 8 
solutions of t-PA complex were treated with continuous wave ultrasound at 1 MHz with an 9 
intensity of 0.75 W/cm
2
 for 5 min. Then, the t-PA activity of solution exposed to ultrasound 10 
was similarly evaluated to compare with that of untreated solution. 11 
 12 
Cell viability 13 
      Cytotoxicity was assayed for mouse fibroblast L929 cells by using a cell counting kit 14 
(Nacalai Tesque Inc., Kyoto, Japan). The cells were seeded on each well of 96-well cell culture 15 
dish (Corning Inc., NY) at a density of 5000 cells/100 l per a well and cultivated in Eagle’s 16 
MEM (E-MEM) medium containing 10 vol% fetal calf serum (FCS) for 24 hr at 37°C in 5% 17 
CO2 95% air atmosphere. The medium was changed to 90l of the fresh medium, and then 10 18 
l of PBS solution containing complexes of t-PA with gelatin and zinc ions was applied to each 19 
well, followed by incubation for 48 hr. Then, the medium was changed to 100 l of E-MEM 20 
medium containing 21 
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium 22 
(WST-8) and incubated further for 2 hr. The absorbance of medium was measured at 450 nm by 23 
the VERSAmax microplate reader (Molecular Devices, Sunnyvale CA). The percentage of cell 24 
viability was expressed as 100% for non-treated cells. The experiment was done 6 times 25 
 7 
 
independently for each sample. 1 
 2 
Body distribution tests of t-PA complexes with gelatin and zinc ions 3 
    The body distribution of complexes of t-PA with gelatin and zinc ions was evaluated for 4 
6-week-old female ddY mice (Simizu Laboratory Supplies Co., Ltd., Kyoto, Japan) as 5 
described previously (Kushibiki et al., 2004b). Briefly, t-PA was radioiodinated according to 6 
the chloramine T method (Wilbur et al., 1989). The t-PA complexes were similarly prepared by 7 
the procedure described above other than using 
125
I-labeled t-PA. The 
125
I-labeled t-PA and the 8 
complexes with gelatin and zinc ions were administered into the tail vein of mice in a PBS 9 
volume of 100 l. At different time intervals after administration, the blood samples were 10 
collected from the eye orbit. The radioactivity of blood was counted on the gamma counter 11 
(ARC-301B, Aloka, Tokyo, Japan). The percentage of radioactivity remaining was expressed 12 
as 100% for the radioactivity of t-PA initially administrated. 13 
At 60 min after administration, the mice were sacrificed and their tissues and organs were 14 
excised and rinsed quickly with cold water to remove the surface blood. Then, the radioactivity 15 
of tissues and organs was counted as described above. The animal experiments were carried out 16 
according to the Institutional Guidance of Kyoto University on Animal Experimentation. The 17 
experiment was done 6 times independently for each sample at each time point. 18 
 19 
Statistical analysis 20 
The statistical analysis was performed using an unpaired Student’s t test. All the data were 21 







Characterization of t-PA complexes with gelatin and zinc ions 2 
Figure 1 shows the apparent molecular size of gelatin with different molecular weights, the 3 
complexes of t-PA and zinc ions. The apparent molecular size of gelatins with molecular 4 
weights ranging from 2,000 to 5,000 could not be measured because of their too small size. The 5 
molecular weight size of gelatin tended to increase with the increased molecular weight. The 6 
apparent molecular size of gelatin was increased by the addition of zinc ions. Irrespective of the 7 
molecular weight of gelatin, the apparent molecular size was dramatically changed by mixing 8 
with t-PA and zinc ions. The size of t-PA complexes tended to decrease with an increase in the 9 
molecular weight of gelatin. 10 
 11 
Thrombolytic activity of t-PA complexes with gelatin and zinc ions 12 
Figure 2 shows the t-PA activity change by the complexation with gelatin of different 13 
molecular weights and zinc ions. Irrespective of the gelatin molecular weight, the thrombolytic 14 
activity of t-PA was significantly suppressed by the complexation with gelatin and zinc ions 15 
(Figure 2A). The suppression tended to become stronger with a decrease in the molecular 16 
weight of gelatin. Figure 2B shows the t-PA activity change of complexes with gelatins and 17 
zinc ions in the presence of BSA. Interestingly, the suppression was weaker with a decrease in 18 
the molecular weight of gelatin. From the viewpoint of activity suppression, the following 19 
experiment was performed for the gelatin with a molecular weight of 100,000. Figure 3 shows 20 
change in the t-PA activity by complexing with zinc ions and gelatin at different concentrations. 21 
The activity of t-PA complexes tended to decrease with an increase in the concentration of 22 
gelatin, and then leveled off at the gelatin concentrations of 10 mg/ml and higher. When 23 
fractionated by a gel filtration column, the t-PA containing ratio of t-PA complexes at the 24 
gelatin concentrations of 10 mg/ml was approximately 84%. 25 
 9 
 
Effect of metal ions on thrombolytic activity of t-PA complexes with gelatin  1 
     Figure 4 shows the activity change of t-PA by complexation with gelatin and various types 2 
of metal ions. The t-PA activity was significantly suppressed by complexing with gelatin and 3 
every metal ions tested in this study (Figures 4A-C), although the t-PA activity was not 4 
suppressed by complexation with gelatin alone (data not shown). The suppression extent 5 
increased in a dose-dependent manner. Among zinc, magnesium, and calcium ions, the 6 
thrombolytic activity of complexes was suppressed most strongly with zinc ions. In addition, 7 
the stability of t-PA complexes with magnesium and calcium ions in serum was lower than that 8 
with zinc ions (data not shown). After ultrasound exposure, the suppressed t-PA activity of 9 
gelatin and zinc ions complexes was recovered to the level of original t-PA activity at the zinc 10 
concentrations of 5 mM or lower (Figure 4D).  11 
Figure 5 shows the activity of t-PA in the presence of zinc ions at different concentrations. 12 
No decrease in the t-PA activity was observed at the zinc concentrations of 5 mM and lower. 13 
     Figure 6 shows the t-PA activity change of complexes by addition of different 14 
concentrations of EDTA, metal chelator. The suppressed t-PA activity of complexes tended to 15 
increase with an increase in the concentration of EDTA. 16 
 17 
Cell viability of t-PA complexes with gelatin and zinc ions 18 
Figure 7A shows the cytotoxicity of t-PA complexes with gelatin and zinc ions. The 19 
complexes showed over 90% cell viability at the concentrations of 200 g/ml and lower.  20 
However, the cell viability gradually decreased at the concentrations of 300 g/ml and higher. 21 
Zinc ions, gelatin, and t-PA alone showed over 90% cell viability at the concentrations of 50 22 
g/ml, 50 g/ml and lower, respectively (Figures 7B, C). The concentration of zinc 23 
ions, gelatin, and t-PA used for complexation in the in vivo experiment were 2 M, 4 g/ml, 24 
and 0.2 g/ml, respectively, which is much lower than those of cytotoxicity.  25 
 10 
 
Body distribution of t-PA and t-PA complexes with gelatin and zinc ions  1 
     Figure 8A shows the percentage of radioactivity remaining in the blood circulation 2 
following intravenous administration of 
125
I-labeled t-PA and the complexes. The radioactivity 3 
remaining was significantly higher for the complexes of gelatin and zinc ions than that of free 4 
t-PA over the time range studied. The blood concentration of free t-PA was rapidly reduced 5 
after administration. Complexation with gelatin and zinc ions prolonged the blood half-life of 6 
t-PA about 3 times. Figure 8B shows the tissue distribution of t-PA complexes with gelatin and 7 
zinc ions or free t-PA. The similar body distribution pattern was observed between the two 8 




















Several DDS trials of t-PA have been reported for the thrombotic diseases of myocardial 2 
infarction and ischemic stroke with various carriers. Liposomes encapsulating t-PA 3 
(Tiukinhoy-Laing et al., 2007; Shaw et al., 2009; Heeremans et al., 1995; Smith et al., 2010), or 4 
poly-(lactide-co-glycolide) microspheres incorporating t-PA and coated with Arg-Gly-Asp 5 
peptide, which is a minimal cell-recognizable peptide of adhesion protein, significantly 6 
accelerated thrombolysis in vitro (Chung et al., 2008). Combination of t-PA with microbubble 7 
induced the acceleration of ultrasound-enhanced thrombolysis in a model of acute stroke 8 
(Molina et al., 2006; Collis et al., 2010).  9 
This study is undertaken to design a novel ultrasound-responsive t-PA delivery system with 10 
gelatin and zinc ions. Gelatin has been used for the controlled release of various drugs, proteins, 11 
and genes because of the good biodegradability and biocompatibility (Veis, 1965; Ikada and 12 
Tabata, 1998; Yamamoto et al., 1998, 2000; Ozeki et al., 2001; Kushibiki et al., 2004a; Aoyama 13 
et al., 2003; Lin et al., 2009; Nakamura et al., 2008; Tanigo et al., 2010; Konishi et al., 2003). 14 
The thrombolytic activity of t-PA was suppressed by the complexation with gelatin and zinc 15 
ions under the optimal condition, and recovered only when exposed to ultrasound. This 16 
ultrasound-induced recovery of t-PA activity is an ideal system considering several problems to 17 
be resolved clinically, such as the bleeding complication and the short half-life in vivo.  18 
t-PA is a globular protein with an molecular weight of about 70,000  (Rijken and Lijnen, 19 
2008; Hedstrom, 2002) and the zeta potential is negative (data not shown). Therefore, it is 20 
expected that the t-PA molecule can electrostatically interact with gelatin (IEP = 9.0). The KD 21 
value between gelatin and t-PA was measured to be 7.01  10-8 M by the quarts crystal 22 
microbalance analysis. For example about specific interaction, previous surface plasmon 23 
resonance analysis indicated that KD between the collagen-binding domain (CBD) from 24 
Clostridium histolyticum collagenase and mini-collagen peptide was 5.72  10-5 M (Wilson et 25 
 12 
 
al., 2003). These results suggested that the interaction of t-PA and gelatin molecules for 1 
complexation was stronger than that of specific interaction between the CBD and the collagen 2 
peptide. However, the t-PA activity was not suppressed by complexation with gelatin (data not 3 
shown). It is highly conceivable that the t-PA molecules do not always interact with gelatin in 4 
the manner to biologically suppress the t-PA activity. Therefore, metal ions were added to 5 
modify the interaction between the gelatin and t-PA molecles.  6 
The analysis on the nonredundant proteins structures from the Protein Data Bank showed 7 
that the most abundant metal ion in the body is Mg
2+

















(Dokmanić et al., 2008). Based on this, considering the toxicity nature 9 






 ions were tested in this study (Figure 4). The 10 
t-PA activity of complexes was most strongly suppressed by the addition of Zn
2+
 ions. It is 11 
likely that the t-PA and gelatin molecules of complexes was modified by a coordinate bond and 12 
an ionic bond with Zn
2+





ions. The apparent molecular size of gelatin was dramatically changed by t-PA and Zn
2+
 ions 14 
complexation. It tended to increase with a decrease in the molecular weight (Figure 1). The 15 
thrombolytic activity of t-PA tended to suppress more strongly by the complexion with gelatin 16 
and zinc ions when the molecular weight of gelatin decreased (Figure 2A). The SDS-PAGE 17 
analysis and atomic absorption photometer revealed that the complexes of gelatin and t-PA, 18 
when fractionated by a gel filtration column, were contained zinc ions (data not shown). 19 
Moreover, no decrease in the t-PA activity was observed at the zinc concentrations of 5 mM and 20 
lower (Figure 5). With gelatin molecules, the t-PA activity was suppressed at low 21 
concentrations of zinc ions, although the t-PA activity was maintained without gelatin. 22 
Additionally, the suppression extent of t-PA activity tended to increase with an increase in the 23 
concentration of gelatin (Figure 3). Taken together, we can say with certainty that the 24 
interaction between the t-PA and gelatin molecules can be reinforced by mixing zinc ions, 25 
 13 
 
resulting in the suppressed biological activity. The amino acid residues contributing to the 1 
coordination bonds with zinc ions are Cys, His, Asp, and Glu in the metalloproteins (Dokmanić 2 
et al., 2008). For the present t-PA complexes, the carboxyl, hydroxyl, and amino groups of 3 
gelatin and t-PA were considered to contribute to the coordination bond with zinc ions, while 4 
the carboxyl groups also contribute to the ionic bond. Taken together, it is highly speculated 5 
that t-PA molecules electrostatically interact with gelatin ones to form their complex, and 6 
additionally, the complex becomes stable through the coordination bond with zinc ions 7 
between the carboxyl, hydroxyl, and amino groups of the two proteins.  8 
The t-PA activity of complexes depended on the molecular weight of gelatin used (Figure 9 
2). This can be explained by the mobility of gelatin molecules. The molecular mobility of 10 
lower molecular weight gelatin to interact is high compared with that of higher molecular 11 
weight gelatin. Therefore, it is highly conceivable that the t-PA molecules of negative charge 12 
interact more with smaller gelatin molecules of positive charge, resulting in the larger 13 
molecular size of t-PA complexes (Figure 1). The more interaction would cover t-PA molecules 14 
more to suppress the activity to a higher extent (Figure 2A). However, the effect of gelatin 15 
molecular weight on the t-PA activity in the presence of BSA was different. The smaller gelatin 16 
showed the higher percent t-PA activity (Figure 2B). This suggests that the BSA presence 17 
enabled the t-PAgelatin complexes to dissociate. The electrostatic interaction between smaller 18 
gelatin and t-PA molecules is weaker than that of larger gelatin ones. In addition, the smaller 19 
gelatin molecules have the higher mobility. As the result, it is likely that small gelatin are 20 
readily detached from the t-PA molecules and bound to BSA ones. On the other hand, it is 21 
demonstrated that albumin has a high-affinity zinc binding site consisting of His67 and Asn99 22 
from domain I and His247 and Asp249 from domain II (Lu et al., 2008; Stewart et al., 2003).
 
23 
This binding may allow the gelatin and BSA interaction to stabilize, resulting in the increased 24 
existence of free t-PA. Based on the stability of t-PAgelatin complexes in the solution, the 25 
 14 
 
molecular weight of gelatin 100,000 was selected for the t-PA complexes formation. 1 
     It is apparent in Figure 4D that the ultrasound irradiation allowed the t-PA activity to recover 2 
to the original level. This is because the interaction forces between the t-PA and gelatin 3 
molecules in the presence of zinc ions were not so strong to allow dissociation by the 4 
ultrasound stimulus. In addition, the ultrasound irradiation did not lose the t-PA activity. In this 5 
study, the conditions of ultrasound were a frequency of 1 MHz and an intensity of 0.75 W/cm
2
 6 
in in vitro experiments. To date, various ultrasound energy levels (0.216 W/cm2) and 7 
frequencies (20 kHz2 MHz) have been used for thrombolysis (Tsivgoulis et al., 2008; 8 
Ishibashi et al., 2002). The majority of studies used of 1 MHz both in vitro and in vivo 9 
(Ishibashi et al., 2002), and the frequency is typically lower than that of diagnostic applications. 10 
Recently, 1 MHz and 0.75 W/cm
2
 ultrasound significantly enhanced tPA-induced 11 
pharmacological lysis of platelet-rich thrombus (recanalization ratio; 90%) with no distal 12 
embolization by fragmented thrombi (Kawata et al., 2007). Taken together, the present 13 
ultrasound conditions will be safe and effective for sonothrombolysis in the femoral artery 14 
model. 15 
    It is recognized that some metal ions sometimes show cytotoxicity. Yamamoto et al. 16 
evaluated 43 metal salts for cytotoxicity using MC3T3-E1 and L929 cells (Yamamoto et al., 17 
2004). K2Cr2O7, CdCl2, VCl3, AgNO3, HgCl2, SbCl3, BeSO4, and InCl3 are high toxic salts in 18 




 for both or either of the cell lines. The cytotoxicity 19 
experiments demonstrated that the complexes with zinc ions showed almost no cytotoxicity 20 
even at a gelatin concentration of 200 g/ml (Figure 7). The concentration of t-PA, gelatin, and 21 
Zn ions used for complexation in the in vivo experiment were 0.2 g/ml, 4 g/ml, and 2 M, 22 
respectively, which is much lower than those of cytotoxicity.  At the concentration of t-PA, 23 
gelatin, or Zn ions alone, no cytotoxicity was observed. It is conceivable that upon ultrasound 24 
exposure, the components of complex and their combinations are released out. I do not think 25 
 15 
 
that the combination of components brings about any cytotoxicity. Therefore, we believe that 1 
the t-PA complexes with gelatin and Zn ions after the application of ultrasound irradiation have 2 
no cytotoxicity in the in vivo experiment.  3 
      The t-PA used in this study is mutant t-PA, monteplase (Verstraete, 1999; Inoue et al., 2004),
 
4 
where Cys84 is substituted with Ser in the epidermal growth factor domain of human t-PA. It is 5 
reported that the half-life is about 20 min (Verstraete, 1999), which is similar to the present 6 
result (Figure 8A). The complexation with the gelatin and zinc ions enabled t-PA to prolong the 7 
half-life in the blood circulation. This is because the apparent molecular size of t-PA was 8 
reduced by the complexation. Complexing with the gelatin and zinc ions, the apparent 9 
molecular size of t-PA became 95 nm (Figure 1). It is reported that the size of long-circulating 10 
particles should not exceed 200 nm (Moghimi et al., 2001). In addition, the resistance of t-PA 11 
against enzymatic degradation will also be increased by the gelatin complexation. Generally, 12 
the biological activity of proteins is protected from enzymatic attack through their 13 
modifications with polymer carriers (Sehgal and Srinivasan, 2009). The in vitro stability of 14 
t-PA in the mouse serum significantly increased by complexing with gelatin and zinc ions with 15 
the molecular weight of gelatin 20,000 or higher (data not shown). The complexes 16 
administered intravenously retained in the blood circulation for prolonged time periods, while 17 
the in vivo stability of t-PA was enhanced due to an increased resistance against enzymatic 18 
degradation. It has been reported that proteins and peptides encapsulated in poly(lactic/glycolic 19 
acid) microparticles are stabilized by their complexating with zinc ions (Schwendeman, 2002; 20 
Lam et al., 2001; Carino et al., 2000; Lam et al., 2000; Yamagata et al., 2003). In addition, the 21 
coordination bonds with zinc ions contribute to the stabilization of endostatin and -crystallin 22 
structures (Han et al., 2007; Biswas and Das, 2008). 23 




 ions has been 24 
investigated (George and Abraham, 2006; Jay and Saltzman, 2009; Jay et al., 2008; Colinet et 25 
 16 
 
al., 2009; Chueh et al., 2010). The pH- and UV-sensitive alginate hydrogels cross-linked with 1 
calcium ions were reported (Colinet et al., 2009; Chueh et al., 2010). However, 2 
ultrasound-responsive carriers modified with metal ions have not been reported. The present 3 
study clearly demonstrates that the metal ions modification was effective in the stabilization of 4 
ultrasound-responsive drug carrier through the cross-linking. Many ultrasound-triggered drug 5 
release with other systems, such as pluronic micelles (Rapoport et al., 2002; Marin et al., 2001), 6 
acoustically active liposomes (Daocheng and Mingxi, 2008), the fluoride anion modified with 7 
a gelatin nanogel (Frinking et al., 1998), have been reported. Tiukinhoy-Laing et al. reported 8 
that t-PA loaded-echogenic liposomes increased 1.5 times of clot lysis with the t-PA 9 
loaded-liposome alone by ultrasound at 1 MHz and 2 W/cm
2
 for 2 min (Tiukinhoy-Laing et al., 10 
2007). In this study, t-PA complexes with gelatin and zinc ions increased about 2 times of t-PA 11 
activity compared with the original level by ultrasound at 1 MHz and 0.75 W/cm
2
 for 5 min. It 12 
is highly speculated that the ultrasound power dissociates the interaction of t-PA and gelatin 13 
complexes by cavitation effect which generates shock waves and high-speed fluid microjets 14 
(Deckers et al., 2008). From the data comparison, we can say that our delivery system is a 15 
sensitive and effective ultrasound-responsive system. For the t-PA complexes at the optimal 16 
concentration of zinc ions, the t-PA activity could be recovered by ultrasound irradiation. In the 17 
previous study, free t-PA administration with or without ultrasound was effective in 18 
recanalization, although there were the adverse effects to be resolved (Kawata et al., 2007). On 19 
the contrary, the complexation with gelatin will suppress the adverse effect of t-PA. The t-PA 20 
activity is suppressed, but locally recovered upon the ultrasound irradiation around the site 21 
necessary.  22 
Combination of a thrombolytic agent and ultrasound enhanced thrombolysis for stroke and 23 
acute myocardial infarction (Alexandrov et al., 2004; Eggers et al., 2003; Cohen et al., 2003). 24 
In the investigations, it is suggested that the direct transmission of energy and the acoustic 25 
 17 
 
cavitation with low-frequency and high-intensity ultrasound broke clots into small fragments 1 
(Rosenschein et al., 1994), promote the penetration of t-PA molecules into the thrombus, the 2 
radiation force to facilitate the reformation, and opening of fibrin matrix, and enhance the drug 3 
diffusion, and the direct effects on the binding of t-PA to the fibrin clot are the mechanisms of 4 
ultrasound on the enhanced thrombolysis (Tiukinhoy-Laing et al., 2007). In the future, we plan 5 
further studies of evaluation of the thrombolytic effect of t-PA complexes with or without the 6 
local ultrasound irradiation around the infarction site of blood vessels in rabbit and swine 7 
thrombosis models. 8 
 9 
CONCLUSION 10 
   Novel and promising ultrasound-responsive nano gelatin complexes of t-PA stabilized by 11 
zinc ions were designed. This system is safe, simple, and convenient to permit the treatment of 12 
acute myocardial infarction while performing diagnosis at the same time even in emergency 13 
conditions. Moreover, the delivery system is also applicable to other therapeutic drugs for the 14 
medical treatment of various diseases. 15 
 16 
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FIGURE LEGENDS 1 
Figure 1. The apparent molecular size of gelatin with different molecular weights (final 2 
concentration: 10 mg/ml) and the complexes of t-PA (0.5 mg/ml) and zinc ions (5 mM) : (○) 3 
t-PA complexes with gelatin and zinc ions, (●) gelatin complexes with zinc ions, and (∆) free 4 
gelatin. 5 
 6 
Figure 2. Change in the t-PA activity by complexing with gelatin (10 mg/ml) and zinc ions (5 7 
mM) as a function of gelatin molecular weight in PBS (A) or BSA solution (B). The percent 8 
t-PA activity was expressed as 100% for free t-PA without zinc ions.  P < 0.05; significant 9 
against the activity of free t-PA. 10 
 11 
Figure 3. Change in the t-PA activity of complexes with different concentrations of gelatin 12 
(Mw = 100,000), t-PA (0.5 mg/ml), and zinc ions (5 mM). The percent t-PA activity was 13 
expressed as 100% for free t-PA without zinc ions.  P < 0.05; significant against the activity 14 
of free t-PA. 15 
 16 
Figure 4. Change in the t-PA activity of complexes with gelatin (Mw = 100,000, 10 mg/ml) and 17 
zinc (A), magnesium (B), and calcium ions (C) at different concentrations. (D) Change in the 18 
t-PA activity of t-PA complexes of gelatin and zinc ions by ultrasound irradiation. The percent 19 
t-PA activity was expressed as 100% for free t-PA without zinc ions.  P < 0.05; significant 20 
against the activity of free t-PA (t-PA).  21 
 22 
Figure 5. The activity of t-PA (0.5 mg/ml) in the presence of zinc ions at different 23 
concentrations. The percent t-PA activity was expressed as 100% for free t-PA without zinc 24 
ions.  P < 0.05; significant against the activity of free t-PA.  25 
 26 
 
Figure 6. Effect of EDTA addition on the t-PA activity of complexes with gelatin (Mw = 1 
100,000, 10 mg/ml) and zinc ions (5 mM). The percent t-PA activity was expressed as 100% for 2 
free t-PA without zinc ions.  P < 0.05; significant against the activity of free t-PA. 3 
 4 
Figure 7.   (A) Cell viability of t-PA complexes with gelatin (Mw = 100,000) and zinc ions. (B) 5 
Cell viability of zinc ions. (C) Cell viability of 500 g/ml of gelatin (Mw = 100,000) and 50 6 
g/ml of t-PA. The percentage of cell viability was expressed as 100% for non-treated cells.  7 
P < 0.05; significant against the viability of non-treated cells. The dotted line indicates 100% of 8 
cell viability. 9 
 10 
Figure 8.   Time profiles of body distribution of t-PA complexes with gelatin (Mw = 100,000, 11 
10 mg/ml) and zinc ions (5 mM) or free t-PA after intravenous administration. After the 12 
intravenous administration of 
125
I-labeled t-PA at different forms to mice, the radioactivity 13 
remaining was measured to evaluate their body distribution. (A) Retention in the blood 14 
circulation: (○) t-PA complexes with gelatin and zinc ions and (●) free t-PA. P < 0.05; 15 
significant against the radioactivity remaining of free t-PA at the corresponding time. (B) 16 
Tissue distribution; t-PA complexes with gelatin and zinc ions (white column) and free t-PA 17 
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